First line raltegravir/emtricitabine/tenofovir combination in HIV-2 infection: phase 2 non-comparative trial (ANRS 159 HIV-2)
| dc.rights.license | open | en_US |
| dc.contributor.author | MATHERON, S. | |
| dc.contributor.author | DESCAMPS, D. | |
| dc.contributor.author | GALLIEN, S. | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | BESSEGHIR, Amel | |
| dc.contributor.author | SELLIER, P. | |
| dc.contributor.author | BLUM, L. | |
| dc.contributor.author | MORTIER, E. | |
| dc.contributor.author | CHARPENTIER, C. | |
| dc.contributor.author | TUBIANA, R. | |
| dc.contributor.author | DAMOND, F. | |
| dc.contributor.author | PEYTAVIN, G. | |
| dc.contributor.author | PONSCARME, D. | |
| dc.contributor.author | COLLIN, F. | |
| dc.contributor.author | BRUN-VEZINET, F. | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | CHENE, Geneviève | |
| dc.date.accessioned | 2020-12-07T10:57:44Z | |
| dc.date.available | 2020-12-07T10:57:44Z | |
| dc.date.issued | 2018-09-28 | |
| dc.identifier.issn | 1537-6591 (Electronic) 1058-4838 (Linking) | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/21322 | |
| dc.description.abstractEn | Background: New options for first-line treatment of HIV-2 infection are needed. We evaluated an integrase inhibitor (raltegravir)-containing regimen. Methods: ART-naive adults infected with HIV-2 only and history of CDC group B or C event, or a CD4 count <500 cells/muL, or a CD4 decrease >50 cells/muL/year over the past 3 years, or a confirmed plasma HIV-2 RNA (pVL) >/=100 copies (cp)/mL were eligible for this non-comparative trial. The composite primary endpoint was survival at 48 weeks (W48) without any of the following: CD4 gain from baseline <100 cells/muL, confirmed pVL >/=40 cp/mL from W24, raltegravir permanent discontinuation, incident B or C event. HIV-2 ultrasensitive pVL (uspVL) and total DNA were assessed using "in-house" PCR assays. Results: Baseline median CD4 count of 30 enrolled individuals (67% women) was 436 cells/microL (InterQuartile Range[IQR] 314- 507); pVL was >/=40 cp/mL in 20/30 (67%); uspVL was >/=5 cp/mL in 23/25 (92%); total DNA was >6 cp/PCR in 8/25 (32%). At W48, the composite endpoint of success was reached in 12/30 (40%; 95% Confidence Interval 22.7 to 59.4). Failure was mainly due to CD4 gain <100 cells/microL (n=15), UspVL was <5 cp/mL in 13/15 (87%) and total DNA >6 cp/PCR in 3/26 (12%). Median CD4 gain was +87 cells/microL (IQR +38- +213, n=28). No serious adverse reaction was reported. Conclusion: Raltegravir-containing cART is a safe option for first line treatment of HIV-2 infection, yielding a comparable success rate to protease inhibitors. UspVL and total DNA were undetectable in the vast majority of participants. | |
| dc.language.iso | EN | en_US |
| dc.rights | Attribution-NonCommercial-NoDerivs 3.0 Unported (CC BY-NC-ND 3.0) | |
| dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/3.0/ | |
| dc.subject.en | MORPH3Eus | |
| dc.title.en | First line raltegravir/emtricitabine/tenofovir combination in HIV-2 infection: phase 2 non-comparative trial (ANRS 159 HIV-2) | |
| dc.title.alternative | Clin Infect Dis | en_US |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1093/cid/ciy245 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
| dc.identifier.pubmed | 29590335 | en_US |
| bordeaux.journal | Clinical Infectious Diseases | en_US |
| bordeaux.page | 1161-1167 | en_US |
| bordeaux.volume | 67 | en_US |
| bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - U1219 | en_US |
| bordeaux.issue | 8 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.team | MORPH3Eus | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| hal.identifier | hal-03164872 | |
| hal.version | 1 | |
| hal.date.transferred | 2021-03-10T10:33:48Z | |
| hal.export | true | |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Clinical%20Infectious%20Diseases&rft.date=2018-09-28&rft.volume=67&rft.issue=8&rft.spage=1161-1167&rft.epage=1161-1167&rft.eissn=1537-6591%20(Electronic)%201058-4838%20(Linking)&rft.issn=1537-6591%20(Electronic)%201058-4838%20(Linking)&rft.au=MATHERON,%20S.&DESCAMPS,%20D.&GALLIEN,%20S.&BESSEGHIR,%20Amel&SELLIER,%20P.&rft.genre=article |
